ContraFect Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ContraFect.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 28.5% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Nov 2023 |
Recent future growth updates
Recent updates
Contrafect GAAP EPS of -$0.46 misses by $0.13
Aug 15ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial
Jul 13ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans
Jun 29Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Dec 25ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market
Sep 15We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate
Aug 18Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?
May 01Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?
Mar 09Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?
Jan 15What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?
Nov 24Contrafect EPS beats by $0.16
Nov 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | N/A | N/A | N/A | N/A | 1 |
12/31/2024 | N/A | N/A | N/A | N/A | 1 |
12/31/2023 | N/A | N/A | N/A | N/A | 1 |
9/30/2023 | N/A | -24 | -36 | -36 | N/A |
6/30/2023 | N/A | -36 | -37 | -37 | N/A |
3/31/2023 | N/A | -46 | -43 | -43 | N/A |
12/31/2022 | N/A | -65 | -46 | -46 | N/A |
9/30/2022 | N/A | -60 | -45 | -45 | N/A |
6/30/2022 | N/A | -48 | -46 | -46 | N/A |
3/31/2022 | N/A | -35 | -44 | -44 | N/A |
12/31/2021 | N/A | -20 | -41 | -41 | N/A |
9/30/2021 | N/A | -22 | -40 | -40 | N/A |
6/30/2021 | N/A | -14 | -37 | -37 | N/A |
3/31/2021 | N/A | -26 | -35 | -35 | N/A |
12/31/2020 | N/A | -28 | -33 | -33 | N/A |
9/30/2020 | N/A | -32 | -33 | -33 | N/A |
6/30/2020 | N/A | -41 | -29 | -29 | N/A |
3/31/2020 | N/A | -32 | -28 | -28 | N/A |
12/31/2019 | N/A | -13 | -27 | -27 | N/A |
9/30/2019 | N/A | 3 | -27 | -27 | N/A |
6/30/2019 | N/A | 4 | -29 | -29 | N/A |
3/31/2019 | N/A | -7 | -27 | -27 | N/A |
12/31/2018 | N/A | -38 | -26 | -26 | N/A |
9/30/2018 | N/A | -48 | -25 | -25 | N/A |
6/30/2018 | N/A | -46 | -25 | -25 | N/A |
3/31/2018 | N/A | -28 | -25 | -25 | N/A |
12/31/2017 | N/A | -16 | -25 | -25 | N/A |
9/30/2017 | N/A | -10 | -27 | -27 | N/A |
6/30/2017 | N/A | -19 | N/A | -29 | N/A |
3/31/2017 | N/A | -26 | N/A | -29 | N/A |
12/31/2016 | N/A | -29 | N/A | -29 | N/A |
9/30/2016 | N/A | -37 | N/A | -27 | N/A |
6/30/2016 | N/A | -32 | N/A | -25 | N/A |
3/31/2016 | N/A | -29 | N/A | -24 | N/A |
12/31/2015 | N/A | -25 | N/A | -22 | N/A |
9/30/2015 | N/A | -22 | N/A | -20 | N/A |
6/30/2015 | N/A | -33 | N/A | -20 | N/A |
3/31/2015 | N/A | -34 | N/A | -17 | N/A |
12/31/2014 | N/A | -35 | N/A | -15 | N/A |
9/30/2014 | N/A | -41 | N/A | -14 | N/A |
6/30/2014 | N/A | -29 | N/A | -12 | N/A |
3/31/2014 | N/A | -24 | N/A | -13 | N/A |
12/31/2013 | N/A | -24 | N/A | -14 | N/A |
9/30/2013 | N/A | -19 | N/A | -15 | N/A |
6/30/2013 | N/A | -20 | N/A | -16 | N/A |
3/31/2013 | N/A | -20 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CFRX's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if CFRX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CFRX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CFRX's revenue is forecast to grow faster than the US market.
High Growth Revenue: CFRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CFRX's Return on Equity is forecast to be high in 3 years time